/R E P E A T -- Diagnocure announces the formation of a new Strategic Advisory Board/



    QUEBEC CITY, Aug. 4 /CNW Telbec/ - DiagnoCure Inc. (TSX: CUR), a life
sciences company commercializing high-value cancer diagnostic tests and
delivering laboratory services, announced today that four prominent colorectal
cancer key opinion leaders have agreed to serve on the Strategic Advisory
Board of its wholly owned subsidiary, DiagnoCure Oncology Laboratories.
    The Strategic Advisory Board is composed of Dr. Edith Mitchell, MD, FACP,
Clinical Professor of Medicine & Medical Oncology at Jefferson Kimmel Cancer
Center; Dr. Stanley R. Hamilton, MD, Professor and Head, Division of Pathology
& Laboratory Medicine at the MD Anderson Cancer Center; Dr. Daniel J. Sargent,
Ph.D., Professor of Statistics and Oncology and Director of Cancer Statistics
at Mayo Clinic; Dr. Martin R. Weiser, MD, Surgical Oncologist at the Memorial
Sloan-Kettering Cancer Center. Their mandate consists of advising the Company
on a number of issues related to Previstage(TM) GCC and the Company's
commercialization efforts.
    "DiagnoCure is proud to count on these top renowned specialists to
provide critical input on the positioning of the test and its future
improvements," stated John Schafer, President and CEO of DiagnoCure.
    Dr. Hamilton commented on the importance of improving the identification
of colorectal cancer patients who appear to be free of disease after surgical
removal of their tumor but later develop recurrent cancer. "The Previstage(TM)
GCC test may improve upon the staging of colorectal cancer that is the major
basis for the decision on whether or not chemotherapy is given after surgery
to attempt to decrease the likelihood of recurrence. The test appears to
detect metastatic tumor in lymph nodes that is not found by the current
standard pathologic methods and may identify patients who are at higher risk
for recurrence than their pathologic stage indicates."
    "Molecular tests are proving to be important in clinical practice. This
assay has the potential to detect occult metastases and may improve staging
which could ultimately lead to greater confidence for physicians and patients
when selecting treatment options," concluded Dr. Weiser.

    About Previstage(TM) GCC

    Staging a patient with colorectal cancer is crucial because it determines
the patient's course of treatment. Current standard of care requires that
pathologists examine microscopically a thin slice of tissue from the lymph
nodes harvested during the patient's surgery to see if cancer has spread
beyond the intestine. Currently, up to 25 - 30 percent of patients with no
pathologically-positive lymph nodes (stage I and II cancers) later return with
recurrent disease, presumably through occult metastases that have escaped
detection. Most of these patients do not receive additional therapies such as
chemotherapy. Previstage(TM) GCC aims to provide clinicians a significantly
more sensitive assay for staging a patient with colorectal cancer that will
increase their confidence in making critical treatment decisions.
    Strong early data supported the potential importance of the GCC test in
improving the staging of colorectal patients. This resulted in the National
Cancer Institute sponsoring a prospective clinical trial of GCC testing in
colorectal cancer patients conducted over five years. This study has been
completed and the Company's collaborators at Thomas Jefferson University will
continue to present the results of the study at major medical conferences
throughout the year.

    About DiagnoCure

    DiagnoCure (TSX: CUR) is a life sciences company commercializing
high-value cancer diagnostic tests and delivering laboratory services that
increase clinician and patient confidence in making critical treatment
decisions. DiagnoCure is currently preparing to launch the Previstage(TM) GCC
Colorectal Cancer Staging Test, the first GCC-based molecular test for the
management of colorectal cancer. In 2003, the Company entered into a strategic
alliance with Gen-Probe (NASDAQ:   GPRO) for the development and
commercialization of a second- generation test for PCA3, DiagnoCure's
proprietary molecular marker highly specific to prostate cancer. The test is
now available through laboratories in the U.S. using PCA3 analyte specific
reagents (ASR) from Gen-Probe, in Europe as the CE-marked PROGENSA(TM) PCA3 in
vitro assay, and in Canada. In addition to its own research, the Company
intends to acquire or in-license additional promising cancer biomarkers from
both academic and commercial institutions. For more information, visit
www.diagnocure.com.

    Forward-looking statements

    This release contains forward-looking statements that involve known and
unknown risks, uncertainties and assumptions that may cause actual results to
differ materially from those expected. By their very nature, forward-looking
statements are based on expectations and hypotheses and also involve risks and
uncertainties, known and unknown, many of which are beyond DiagnoCure's
control. As a result, investors are cautioned not to place undue reliance on
these forward-looking statements. The forward-looking statements regarding the
outcome of research and development projects, clinical studies and future
revenues are based on management expectations. In addition, the reader is
referred to the applicable general risks and uncertainties described in
DiagnoCure's most recent Annual Information Form under the heading "Risk
Factors". DiagnoCure undertakes no obligation to publicly update or revise any
forward-looking statements contained herein.




For further information:

For further information: Contact: DiagnoCure Inc.: JF Bureau, Chief
Financial Officer, (418) 527-6100, communications@diagnocure.com; Media: U.S.:
Troy Pearson, Mentus Life Science, (858) 455-5500 X320, Troy@mentus.com;
Canada: Jean-Pierre Trudel, Jean-Pierre Trudel & Associates, (514) 347-6111,
jp.trudel@videotron.ca

Organization Profile

DiagnoCure Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890